Rheumatoid arthritis (RA) constitutes one of the main inflammatory chronic diseases
which can lead to important disability and an inflammatory burden including a higher
risk of cardiovascular (CV) disease.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Biologic agents reduce cardiovascular events in rheumatoid arthritis not responsive to tumour necrosis factor inhibitors: a national cohort study.Can J Cardiol. 2020; 36: 1739-1746
- The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.Arthritis Res Ther. 2014; 16 (R127)
- Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis.Arthritis Rheum. 2013; 65 (Westlake SL, Colebatch AN, Baird J, Curzen N, Kiely P, Quinn M, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2011;50:518–31): 334-342
- Systematic review and meta-analysis: anti-tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis.Arthritis Care Res. 2011; 63: 522-529
- EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.Ann Rheum Dis. 2017; 76: 17-28
- Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).Ann Rheum Dis. 2014; 73: 62-68
- Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis.PLoS ONE. Jan 2016; 11e0146991
- Estimated 10-year cardiovascular risk in a large Italian cohort of rheumatoid arthritis patients: data from the Cardiovascular Obesity and Rheumatic DISease (CORDIS) study group.Eur J Intern Med. 2021; https://doi.org/10.1016/j.ejim.2021.10.001
- Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.Eur Heart J. Jun 2003; 24: 987-1003
- Italian cardiovascular mortality charts of the CUORE project: are they comparable with the SCORE charts?.Eur J Cardiovasc Prev Rehabil. 2010; 17: 403-409
- Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.BMJ. 2017; 357: j2099
- 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol. 2014; 63: 2935-2959
- Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.JAMA. Feb 2007; 297 (https://doi,.org/10.1001/jama.297.6.611): 611-619
- Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study.Arthritis Rheumatol. 2015; 67: 1995-2003
- Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.Ann Rheum Dis. 2017; 76: 1057-1063
- Ten-year risk of cerebrovascular accidents in incident rheumatoid arthritis: a population-based study of trends over time.Rheumatology (Oxford). 2021; 60: 2267-2276
- CARMA Project Collaborative Group. Cardiovascular mortality and cardiovascular event rates in patients with inflammatory rheumatic diseases in the CARdiovascular in rheuMAtology (CARMA) prospective study-results at 5 years of follow-up.Rheumatology (Oxford). 2021; 60: 2906-2915
- Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors [abstract].Arthritis Rheumatol. 2021; 73
Article info
Publication history
Published online: December 13, 2021
Accepted:
December 6,
2021
Received:
December 1,
2021
Identification
Copyright
© 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
